In partnership with
Letter from The Editor
Landmark triple therapy trials
ICS: to use or not to use?
MABA, and novel LAMA
Macrolide antibiotics and trial with azithromycin
Introduction
From clinical, anatomical, pathophysiological, and inflammatory subsets to molecular pathways
Treatments targeting type2-inflammation
Late-breaking biologics
Endoscopic treatment of emphysema
Endoscopic treatment of asthma
Endoscopic treatment of chronic bronchitis
Risk stratification
New therapeutic targets: moving form pre-clinical data to phase 2 studies
Balloon pulmonary angioplasty for CTEPH
IPF introduction and Pentraxin-2
Nintedanib and sildenafil
Gastroesophageal reflux, IPF and lessons learned
EGFR-targeted treatments
ALK inhibition, guidelines, liquid biopsies, and immunotherapy
Brain metastases, lung cancer and interstitial lung disease
Top image: © themacx
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP